- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Surya Singh, MD, Explains How Biosimilar Education Has Reduced Provider Doubt
Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.
Surya Singh, MD, is the president of Singh Healthcare Advisors.
Transcript:
Have education efforts reduced provider doubt regarding the similarity of biosimilars and their reference products?
I think that the educational component of biosimilar uptake had a slow start 5 years ago, but has really accelerated now [that we’ve] gotten over what I'll refer to as the educational threshold for providers. So, if the question is, "Is there still lingering doubt in the minds of providers on whether or not a biosimilar is sufficiently comparable to the reference product in order for them to safely prescribe it and have their patient use it?" the answer to that is I don't think there's lingering doubt. I think most of the doubt that was present in the earlier days following the first biosimilar approvals has really been taken care of or eliminated based on the educational efforts that were undertaken by a number of different groups, but also by experience. So, they've gained experience with biosimilar products and realized what a lot of people were saying at the outset: The batch-to-batch variability between the reference product being produced in the same facility was as great as it is between a biosimilar product and the reference product. I think experience has helped a lot of clinicians who had some doubt at the outset get over that doubt. So, I would contend that if there is any lingering doubt that is impeding biosimilar uptake, it pales in comparison to some of the economic considerations that are at play in the market.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
